{"id":2287,"date":"2024-10-01T20:50:00","date_gmt":"2024-10-01T20:50:00","guid":{"rendered":"https:\/\/www.thewisdomstudy.org\/?post_type=pressrelease&p=2287"},"modified":"2025-04-01T21:47:40","modified_gmt":"2025-04-01T21:47:40","slug":"advancing-breast-cancer-care-how-colors-collaboration-with-ucsfs-wisdom-study-is-shaping-risk-based-screening","status":"publish","type":"pressrelease","link":"https:\/\/www.thewisdomstudy.org\/pressrelease\/advancing-breast-cancer-care-how-colors-collaboration-with-ucsfs-wisdom-study-is-shaping-risk-based-screening\/","title":{"rendered":"Advancing Breast Cancer Care: How Color\u2019s Collaboration with UCSF\u2019s WISDOM Study is Shaping Risk-Based Screening"},"content":{"rendered":"\n

At Color, we\u2019ve spent nearly a decade pushing the boundaries of delivering care by meeting people where they are at, from our early days in genetic testing to our\u00a0expansion into a comprehensive Virtual Cancer Clinic<\/a>. As Breast Cancer Awareness Month draws to a close, we\u2019re excited to turn the spotlight onto one of the most transformative partnerships we\u2019ve been part of: our collaboration with Dr. Laura Esserman and the groundbreaking\u00a0WISDOM Study.<\/a><\/p>\n\n\n\n

Revolutionizing Breast Cancer Screening: The WISDOM Study<\/strong><\/h3>\n\n\n\n

The WISDOM Study (W<\/strong>omen I<\/strong>nformed to S<\/strong>creen D<\/strong>epending O<\/strong>n M<\/strong>easures of risk), led by Dr. Esserman at the University of California, San Francisco (UCSF), and collaborators nationwide, has been at the forefront of revolutionizing breast cancer screening since its inception in 2016. Instead of a one-size-fits-all approach, the WISDOM Study compares two screening methods: annual mammograms for all women starting at age 40 versus a more personalized screening strategy based on individual risk factors like genetics, breast density, and family history. <\/p>\n\n\n\n

WISDOM\u2019s goal is to continuously improve our approach to screening and prevention for breast cancer. We know breast cancer doesn\u2019t manifest the same for every patient, and treatments are now personalized based on tumor biology. It is time for that knowledge to be brought into how we approach screening \u2014 not everyone has the same risk for developing breast cancer, and we have many tools to help predict who may be at risk for more aggressive types of the disease.<\/p>\n\n\n\n

To date, WISDOM has enrolled nearly 60,000 women nationwide, with nearly 30,000 receiving Color genetic testing to provide them with genetic information about their personalized risk. Last year, WISDOM expanded enrollment to include women starting at age 30 (rather than age 40), aiming to assess risk earlier and offer preventive options to those at higher risk. With breast cancer rates rising<\/a> slightly in younger women, early risk assessment is crucial in determining if screening should begin sooner. Additionally, WISDOM is evaluating polygenic risk, which looks at small genetic changes across many genes. These changes are combined into a polygenic risk score (PRS) that is integrated with the WISDOM risk model, potentially influencing an individual\u2019s overall breast cancer risk. <\/p>\n\n\n\n

Key milestones & findings from the study so far include:<\/p>\n\n\n\n